In vivo and in situ evaluation of innovative approaches in dentin hypersensitivity treatment

BMC Oral Health

Table 6 Pain intensity scores following evaporative testing at different time intervals between and within treatment groups

		PRG	Embrace	Duraphat	p-value
Baseline	Mean [± SD]	8.8^aA [± 1.0]	8.9^aA [± 1.1]	8.9^aA [± 0.9]	0.946
Baseline	Median (Range)	9 (7–10)	9 (6–10)	9 (7–10)	0.946
3 min	Mean [± SD]	0.1^aB [± 0.3]	6.1^bB [± 0.8]	6.6^bB [± 0.7]	< 0.001*
3 min	Median (Range)	0 (0–1)	6 (5–8)	7 (6–8)	< 0.001*
2 weeks	Mean [± SD]	0.2^aB [± 0.4]	2.3^bC [± 0.9]	3.5^cC [± 0.7]	< 0.001*
2 weeks	Median (Range)	0 (0–1)	2 (0–4)	3 (2–5)	< 0.001*
4 weeks	Mean [± SD]	0.5^aB [± 0.5]	2.5^bCD [± 0.8]	4.3^cC [± 0.6]	< 0.001*
4 weeks	Median (Range)	1 (0–1)	2 (1–4)	4 (3–6)	< 0.001*
8 weeks	Mean [± SD]	0.5^aB [± 0.5]	3.3^bD [± 0.7]	5.2^cD [± 0.7]	< 0.001*
8 weeks	Median (Range)	1 (0–1)	3 (2–5)	5 (4–6)	< 0.001*
	p-value	< 0.001*	< 0.001*	< 0.001*

* Statistically Significant at p = 0.05
** Values are presented as mean [± SD] and median (range). Statistical significance for between-group comparisons (same row) was determined using Kruskal-Wallis test followed by Dunn’s post hoc test for pairwise comparisons. Within-group comparisons (same column) were analyzed using Friedman test followed by Dunn’s post hoc test for pairwise comparisons

ISSN: 1472-6831